A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)
Status:
Terminated
Trial end date:
2014-07-08
Target enrollment:
Participant gender:
Summary
This adaptive design, dose-ranging study of MK-1029 will assess the dose-related efficacy and
safety of MK-1029 compared with placebo using measures of lung function (forced expiratory
volume in 1 second [FEV1]). The primary objectives are (1) To demonstrate that MK-1029,
compared with placebo, results in dose-related improvements in FEV1 over the last 6 weeks of
the 12-week active-treatment period; and (2) To determine the dose-related safety and
tolerability of MK-1029 as monotherapy and as concomitant dosing with montelukast over 12
weeks. The primary hypothesis is: MK-1029 is superior to placebo in a dose-related fashion in
the average change from baseline in FEV1 over the last 6 weeks of the 12-week
active-treatment period.